PEGylation of alpha-momorcharin: Synthesis and characterization of novel anti-tumor conjugates with therapeutic potential

Biotechnology Letters

Volumn 32, Issue 7, 2010, Pages 883-890

  Bian, Xiaoxiao ^a   Shen, Fubing ^b   Chen, Yiwen ^a   Wang, Baoning ^a   Deng, Mian ^a   Meng, Yanfa ^a  

^a SICHUAN UNIVERSITY   (China)

^b CHENGDU MEDICAL COLLEGE   (China)

Author keywords

Acute toxicity; Alpha momorcharin; Anti tumor activity; Immunogenicity; PEGylation

Indexed keywords

ACUTE TOXICITY; ANTI-TUMOR ACTIVITIES; ANTI-TUMOR AGENTS; ANTI-TUMORS; CLINICAL APPLICATION; IMMUNOGENICITY; IN-VITRO; PEGYLATION; POTENTIAL APPLICATIONS; RIBOSOME-INACTIVATING PROTEIN; SYNTHESIS AND CHARACTERIZATION; THERAPEUTIC POTENTIALS; TUMOR CELLS;

MOTION PICTURE EXPERTS GROUP STANDARDS; POLYMER BLENDS; TOXICITY;

TUMORS;

ANTINEOPLASTIC AGENT; MACROGOL DERIVATIVE; MMC PROTEIN, MOMORDICA CHARANTIA; RIBOSOME INACTIVATING PROTEIN;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CHEMISTRY; HUMAN; IMMUNOLOGY; LD 50; MOUSE; RABBIT; SYNTHESIS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HUMANS; LETHAL DOSE 50; MICE; MICE, INBRED BALB C; POLYETHYLENE GLYCOLS; RABBITS; RIBOSOME INACTIVATING PROTEINS;

EID: 77953821992     PISSN: 01415492     EISSN: 15736776     Source Type: Journal    
DOI: 10.1007/s10529-010-0242-8     Document Type: Article

References (15)

1. Au TK, Collins RA, Lam TL et al (2000) The plant ribosome inactivating proteins luffin and saporin are potent inhibitors of HIV-1 integrase. FEBS Lett 471: 169-172.
2. Bailon P, Berthold W (1998) Polyethylene glycol-conjugated pharmaceutical proteins. Pharm Sci Tech Today 1: 352-356.
3. Caliceti P, Veronese FM (2003) Pharmacokinetic and biodistribution properties of poly (ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 55: 1261-1277.
4. Go TTM, Yeung HW, Fong WP (1992) Deoxyribonucleolytic activity of alpha-momorcharin and beta-momorcharin. Life Sci 51: 1347-1353.
5. Gou LT, Tong AP, Chen LJ et al (2008) Comparative plasma membrane-associated proteomics of immortalized human hepatocytes. Biochem (Moscow) 73: 1200-1206.
6. Grover JK, Yadav SP (2004) Pharmacological actions and potential uses of Momordica charantia: a review. J Ethnopharmacol 93: 123-132.
7. Leung SO, Yeung HW, Leung KN (1987) The immunosuppressive activities of 2 abortifacient proteins isolated from the seeds of bitter-melon (Momordica charantia). Immunopharmacology 13: 159-171.
8. Li ME, Chen YW, Liu ZY et al (2009) Anti-tumor activity and immunological modification of ribosome-inactivating protein (RIP) from Momordica charantia by covalent attachment of polyethylene glycol. Acta Biochim Biophy Sin 41: 782-799.
9. Mock JWY, Ng TB, Wong RNS et al (1996) Demonstration of ribonuclease activity in the plant ribosome-inactivating proteins alpha- and beta-momorchrins. Life Sci 59: 1853-1859.
10. Ng TB, Liu WK, Sze SF et al (1994) Action of α-momorcharin, a ribosome inactivating protein, on cultured tumor cell lines. Gen Pharmacol 25: 75-77.
11. Ren JS, Wang YP, Dong YC et al (1994) The N-glycosidase mechanism of ribosome-inactivating proteins implied by crystal structures of α-momorcharin. Structure 2: 7-16.
12. Stirpe F, Battelli MG (2006) Ribosome-inactivating proteins: progress and problems Cell. Mol Life Sci 63: 1850-1866.
13. Tam PP, Chan WY, Yeung HW (1984) Viability of alpha-momorcharin-treated mouse blastocysts in the pseudopregnant uterus. J Reprod Fertil 72: 567-572.
14. Veronese FM (2001) Peptide and protein PEGylation: a review of problems and solutions. Biomaterials 22: 405-417.
15. Veronese FM, Pasut G (2005) PEGylation, successful approach to drug deliver. Drug Discov Today 10: 1451-1458.